bluejay diagnostics, inc. is a medical diagnostics company focused on improving patient outcomes using its symphony system, a cost-effective, rapid, near-patient product for triage and monitoring of disease progression.
Company profile
Ticker
BJDX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
473552922
BJDX stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
2 Jan 24
424B4
Prospectus supplement with pricing info
29 Dec 23
EFFECT
Notice of effectiveness
28 Dec 23
S-1/A
IPO registration (amended)
27 Dec 23
8-K
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating
27 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
S-1/A
IPO registration (amended)
21 Dec 23
UPLOAD
Letter from SEC
30 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.08 mm | 5.08 mm | 5.08 mm | 5.08 mm | 5.08 mm | 5.08 mm |
Cash burn (monthly) | 7.82 k | 684.37 k | 780.41 k | 864.84 k | 375.02 k | 706.72 k |
Cash used (since last report) | 44.11 k | 3.86 mm | 4.40 mm | 4.88 mm | 2.11 mm | 3.98 mm |
Cash remaining | 5.03 mm | 1.22 mm | 676.59 k | 200.52 k | 2.96 mm | 1.09 mm |
Runway (months of cash) | 643.3 | 1.8 | 0.9 | 0.2 | 7.9 | 1.5 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 45.51 mm |
Total shares | 5.44 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Indranil Dey | 4.09 mm | $14.85 mm |
Douglas Clark Wurth | 1.17 mm | $4.25 mm |
Renaissance Technologies | 49.10 k | $13.00 k |
HRT Financial | 29.91 k | $8.00 k |
Geode Capital Management | 29.14 k | $7.86 mm |
Two Sigma Securities | 27.09 k | $7.12 mm |
Vanguard | 15.90 k | $4.18 mm |
NTRS Northern Trust | 11.70 k | $3.08 mm |
Tower Research Capital | 10.13 k | $2.67 mm |
UBS UBS Group AG - Registered Shares | 5.16 k | $1.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Dec 23 | Indranil Dey | Common Stock | Buy | Acquire P | No | No | 3.27 | 500 | 1.64 k | 28,526 |
13 Dec 23 | Svetlana Dey | Common Stock | Buy | Acquire P | No | No | 3.07 | 500 | 1.54 k | 1,500 |
28 Mar 23 | Indranil Dey | Common Stock | Buy | Acquire P | No | No | 0.44 | 2,000 | 880.00 | 660,538 |
27 Mar 23 | Indranil Dey | Common Stock | Buy | Acquire P | No | No | 0.44 | 8,000 | 3.52 k | 558,538 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
23 Feb 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Jan 24
Gold Moves Lower; US Crude Stocks Decline Last Week
28 Dec 23
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
28 Dec 23
12 Health Care Stocks Moving In Thursday's Intraday Session
28 Dec 23
Press releases
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
2 Jan 24
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
28 Dec 23
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
27 Dec 23